
Aravax
Early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Employees
Enterprise value
$168—252m
Authorizing premium user...
Early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.